Appointed
Allan Reine
member of the Board of Directors
PRME ·
Prime Medicine, Inc.
The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director
Ready 8-Ks
25
Latest filing
May 7, 2026, 7:59 PM ET
Top materiality
1.00
Event mix
other_material ×13 · earnings ×9 · leadership ×2
Sentiment
7 pos · 1 neg · 17 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for PRME
Highest-materiality recent filing
Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus
- Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
- Jeff Marrazzo named Executive Chair of the board.
-
Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs
Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.
-
Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned
Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.
-
Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated
Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.
-
Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027
First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.
-
Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D
Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.
-
Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
-
Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025
Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.
-
AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.
-
Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025
Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.
-
Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront
Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.
-
Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling
GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.
-
Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026
Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.
-
Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial
FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.
-
Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy
Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.
-
Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024
Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.
Executive changes
Departed
Keith Gottesdiener
President, Chief Executive Officer and principal executive officer
PRME ·
Prime Medicine, Inc.
Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company
Appointed
Allan Reine
Chief Executive Officer and principal executive officer
PRME ·
Prime Medicine, Inc.
the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material